Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy (Q33393360)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy |
scientific article |
Statements
1 reference
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy (English)
1 reference
Hope S Rugo
1 reference
Joyce A O'Shaughnessy
1 reference
Howard A Burris
1 reference
Svetislava J Vukelja
1 reference
Charles L Vogel
1 reference
Rachel A Borson
1 reference
Steven Limentani
1 reference
Elizabeth Tan-Chiu
1 reference
Ian E Krop
1 reference
Richard A Michaelson
1 reference
Sandhya Girish
1 reference
Lukas Amler
1 reference
Maoxia Zheng
1 reference
Yu-Waye Chu
1 reference
Barbara Klencke
1 reference
20 December 2010
1 reference
1 reference
Identifiers
1 reference